Drug intelligence / Profile preview

canis lupus familiaris skin extract

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intradermal, Percutaneous
01

Overview

Canis lupus familiaris skin is an allergenic extract derived from the skin and dander (epithelia) of the domestic dog (Canis lupus familiaris). [6, 14] This biological product is used for both the diagnosis and treatment of allergies to dogs in humans. [7, 12] For diagnostic purposes, it is administered as a skin prick test to identify individuals with IgE-mediated sensitivity to dog allergens. [11, 12] For therapeutic use, it is employed in allergen-specific immunotherapy, where gradually increasing doses are administered subcutaneously to desensitize the immune system and induce tolerance, thereby reducing the symptoms of allergic rhinitis or asthma triggered by exposure to dogs. [4, 5, 8] The product is classified as a non-standardized allergenic extract and is distributed by companies such as ALK-Abello, Inc. [3, 7, 17] It was first approved for use in the United States in 1965.

Other names
Dog EpitheliaDog EpitheliumDog skin extractCanis lupus familiaris skin
02

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on canis lupus familiaris skin extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on canis lupus familiaris skin extract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call